Close Menu

bile duct cancer

The FDA approved the drug based on data on response rate but continued approval is contingent on the results of a randomized study showing a PFS and OS advantage.

The CDx, which will include the detection of activating FGFR2 fusions, is expected to be incorporated into Foundation Medicine's FDA-approved FoundationOne CDx assay.

The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.

The researchers are studying the molecular links between bile duct cancer and liver fluke infection, and testing a vaccine to protect against infection.

The Asian cancer biotech firm will use ACT's genomic tools to research why some patients responded unusually well to its pan-HER inhibitor.

NEW YORK (GenomeWeb) – Cancer genetics diagnostics firm NeoGenomics today said that revenues in the second quarter increased 33 percent year over year while test volume increased 40 percent.

NEW YORK (GenomeWeb News) – A pair of Nature Genetics studies by independent research teams explored the genetic glitches characterizing cancers that affect the biliary tract or bile ducts of the liver.

NEW YORK (GenomeWeb News) – A form of bile duct cancer associated with liver fluke infection appears to share some mutation patterns with a pancreatic cancer called pancreatic ductal adenocarcinoma, a new study suggests.

Researchers aim to develop proteomic biomarkers for bile duct cancer resulting from infection by the parasite Opisthorchis viverrini.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.